15th December 2022 – The USPTO has granted the patent application valid by RCSI covering the OncoLize technology. This broad base patent describes the composition-of-matter and various formulations and applications essential to the oncology business that OncoLize develops.

OncoLize will obtain an exclusive, worldwide license to the technology covering all disease categories within Oncology,. The company has full rights to establish its own patent portfolio based on the Licensed IP.

Categories: Other

Leave a Reply

Your email address will not be published. Required fields are marked *